Navigation Links
Pharmaceuticals Announces $1.5 Million Second Closing in Private Placement
Date:1/31/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 31, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.

DelMar announced a first closing of $5.4 million on January 25, 2013.

Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.

Jeffrey Bacha , Chief Executive Officer of DelMar, commented "We are pleased to announce this second closing to raise additional funds and are very encouraged by the overall level of investor interest in our private placement. We continue to enhance our financial position to expand and accelerate our drug development activities with our lead drug candidate, VAL-083." 

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com;
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989

 


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:6/30/2017)... Md. , June 30, 2017 In ... since the start of May, at least ten diagnostic ... include private investments, public offerings and a loan facility.  ... million to almost $80 million.  Kalorama Information provides a ... of its Diagnostics Knowledge Center. ...
(Date:6/27/2017)... TEL AVIV, Israel , June 27, 2017 /PRNewswire/ ... a specialty clinical-stage pharmaceutical company specializing in the development ... ring The Nasdaq Stock Market Opening Bell in ... 28, 2017 in honor of its initial public offering ... Nasdaq Capital Market in March 2017. Dr. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... announced that they have enrolled over 100,000 children in their treatment program. Clubfoot ... every year in areas where treatment is limited or non-existent. Without intervention, these ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
(Date:7/24/2017)... ... July 24, 2017 , ... “The Perfect Gift”: a customizable and interactive Bible study guide ... Huckett is a born-again Christian. She has always accepted Christ as her Savior, yet ... She was in the Spirit when she wrote this book to her children, so they ...
(Date:7/24/2017)... ... ... “Journey to the Light: The Quest for Happiness and Love. . . through ... herself. “Journey to the Light: The Quest for Happiness and Love. . . ... newsletters, manuals, and articles, who has recently decided to expand her literary horizons and ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... education and training standards for healthcare treatment providers, offers healthcare professionals a ... iaedp™ Core Curriculum. , Presented as either online or as a 2-day, ...
Breaking Medicine News(10 mins):